Affordable Access

Publisher Website

How Do Patients With Type 2 Diabetes Mellitus Value the Importance of Outcomes? An Overview of Reviews.

Authors
  • Niño-de-Guzmán, Ena1
  • Bracchiglione, Javier2
  • Vásquez-Mejía, Adrián3
  • de Graaf, Gimon4
  • Rocha Calderón, Claudio5
  • Alonso-Coello, Pablo6
  • 1 Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Cancer Prevention and Control Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Department of Pediatrics, Obstetrics, Gynecology and Preventive Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: [email protected]. , (Spain)
  • 2 Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Valparaíso, Chile; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. , (Chile)
  • 3 Facultad de Medicina Humana, Universidad Nacional Mayor de San Marcos, Lima, Perú.
  • 4 Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. , (Netherlands)
  • 5 Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain. , (Spain)
  • 6 Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. , (Spain)
Type
Published Article
Journal
Value in Health
Publisher
Elsevier
Publication Date
Dec 01, 2023
Volume
26
Issue
12
Pages
1782–1794
Identifiers
DOI: 10.1016/j.jval.2023.07.003
PMID: 37516195
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We aimed to assess how patients value the importance of type 2 diabetes mellitus (T2DM) related outcomes. Overview of systematic reviews (SRs) reporting patients' utilities or disutilities for T2DM outcomes. We searched 3 databases from inception until June 2021. Study selection and data extraction were conducted in pairs. We evaluated the quality of SRs with the Joanna Briggs Institute Checklist, and the overlap with the corrected covered area. We estimated descriptive statistics, and, when possible, conducted metanalysis. We identified 11 SRs, including 119 studies and 70 outcomes. Most reviews were high-quality SRs. The outcomes with the lowest utilities were hypoglycemia with very severe symptoms (acute complications), stroke (macrovascular complications), diabetic peripheral neuropathy with severe pain (microvascular complications), extreme obesity (comorbidities), and insulin only or combined (management of diabetes). Good/excellent glucose control and noninsulin injectable showed higher values than T2DM without complications. The outcomes with the highest disutilities were amputation, depression, major hypoglycemia, stroke, and management using only insulin. We provide standardized, reliable utility values (or associated disutilities) for T2DM, acute, microvascular and macrovascular complications, related comorbidities and treatments that may support judgments when making clinical recommendations, designing decision support tools, and developing interventions and economic analysis. Copyright © 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times